Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Efavirenz on Nemtabrutinib PK in Healthy Participants
NCT06698016Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nemtabrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 3 more, sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-Time Curve from Time 0 to Infinity up to 2 weeks. Started Jul 2023; status: completed.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)Waldenström macroglobulinemia (WM)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06698016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698016.